They slow down digestion, making you eat less
Cell Metabolism, 34(9), 1234-1247.e9
Unsere Experten untersttzen Sie gerne
4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)